Medindia

X

Largest Long-Term Study Confirms EDAP's Ablatherm® HIFU is Effective, Highly Reproducible Primary Treatment for Localized Prostate Cancer

Tuesday, May 17, 2011 General News J E 4
Advertisement
-- 2,552 Patient, International, Multi-Center, 10-year Study Shows 83% of Patients Cancer Free --

Company Contact:

Blandine ConfortInvestor Relations / Legal Affairs+33 4 72 15 31 72bconfort@edap-tms.com

Media/Investors:

Kim Muscara/Stephanie Carrington  646-536-7011/7017 kmuscara@theruthgroup.com scarrington@theruthgroup.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Phreesia Wins TripleTree I Award for its Innovativ...
S
Children's Hospital Boston Ranked #1 by U.S. News ...